Keywords: 3rd-qtr, new, product, sales, deliver, shire, firm
3rd-qtr new product sales deliver for Shire, but the firm posts earnings drop on charges
Article | 10 November 2008
Shire, the UK's third-largest drugmaker, saw its third-quarter 2008 GAAP earnings per American Depository Receipt slump 62% to $0.07 because of charges taken ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
